RT Quanto (@quanto)As of today, @quanto is enabling @RaydiumProtocol Liquidity Pool (LP) tokens as collateral.You can now use your LP tokens as collateral to trade across 500+ markets with full freedom.This unlocks a powerful new layer of capital efficiency:- Continue earning yield from your on-chain LP positions.- Actively trade the markets without missing opportunities.- Hedge against impermanent loss using your own LP tokens.By turning LP tokens into collateral, Quanto expands the universe of what’s trad ...

RT Euler Labs (@eulerfinance)Euler reaching escape velocity.A new milestone crossed: $2B in total borrows.Built to be flexible, built to be capital efficient: Utilisation at 48% with $4B in total deposits. https://t.co/TcVXhAbcAB ...

Key Takeaways Greif finalized the $462M sale of its timberlands unit to Molpus Woodlands Group.The sale covers about 173,000 acres in the Southeastern United States.GEF expects the leverage ratio to fall below 1.2X, strengthening its balance sheet.Greif, Inc. (GEF) announced that it closed the previously stated sale of its timberlands business to Molpus Woodlands Group. This move will help Greif's debt-reduction efforts and boost its capital efficiency.Details of Greif’s Timberlands SaleIn early August, Gre ...

Plasma launch is a great DeFi reset.On Ethereum, first mover advantage helped many protocols hold their lead with sticky TVL.That is why DeFi 1.0 tokens often still trade at higher valuations than newer DeFi assets.Plasma leveled the field.Capital now flows to platforms that deliver security, innovation and capital efficiency, not just legacy brand.Aave unsurprisingly leads by TVL, while Fluid and Euler prove the boring 'capital efficiency' matters as it translates into higher yields for LPs.If more capital ...

RT Brother Lyskey (@0xLyskey)why this is giga-bullish for EkuboEkubo’s core challenge is that concentrated-liquidity pools demand constant, hands-on management. if your position goes out of range, your liquidity stops earning fees and becomes inactive.so to stay profitable you must rebalance frequently, especially because the tighter you concentrate around the active price, the more capital-efficient and fee-generating your position becomes.but doing this manually is hard and expensive, since Ekubo charges ...

Core Insights - CF Bankshares Inc. (CFBK) operates in a competitive banking landscape with peers such as Citizens Community Bancorp, Colony Bankcorp, Community West Bancshares, Citizens Holding Company, and C&F Financial Corporation [1] - CFBK's Return on Invested Capital (ROIC) is -1.19%, significantly below its Weighted Average Cost of Capital (WACC) of 24.98%, indicating inefficiencies in capital utilization [2][5] - The ROIC to WACC ratio for CFBK is -0.048, further emphasizing the company's struggle to generate returns relative to its capital costs [2] - Citizens Community Bancorp (CZWI) has a ROIC of 0.80% and a WACC of 18.82%, resulting in a ROIC to WACC ratio of 0.042, indicating low efficiency in capital utilization [3] - Colony Bankcorp (CBAN) shows a negative ROIC of -0.63% and a WACC of 12.69%, with a ROIC to WACC ratio of -0.050, reflecting similar inefficiencies as CFBK [3] - Community West Bancshares (CWBC) has a ROIC of 4.54% and a WACC of 11.57%, achieving a ROIC to WACC ratio of 0.392, indicating better capital efficiency [4] - C&F Financial Corporation (CFFI) stands out with a ROIC of 6.28% and a WACC of 13.55%, resulting in the highest ROIC to WACC ratio of 0.463 among peers, demonstrating superior capital efficiency [4][5]

Core Insights - AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-based therapies, with its flagship product Ampligen being explored for multiple therapeutic applications [1] - AIM demonstrates exceptional capital efficiency with a Return on Invested Capital (ROIC) of 443.97%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.83%, resulting in a ROIC to WACC ratio of 76.10 [2][6] - In contrast, AIM's peers, including Aytu BioPharma, iBio, Co-Diagnostics, Cocrystal Pharma, and NanoViricides, show negative ROIC to WACC ratios, indicating inefficiencies in capital utilization [3][4][5][6] Company Performance - AIM's ROIC of 443.97% indicates effective use of capital to generate substantial returns, setting it apart from its peers in the biotechnology sector [2][6] - The company's ROIC to WACC ratio of 76.10 highlights its ability to generate returns far exceeding its cost of capital, showcasing strong capital efficiency [2][6] Peer Comparison - Aytu BioPharma has a ROIC of -2.78% and a WACC of 18.15, resulting in a negative ROIC to WACC ratio of -0.15, indicating capital inefficiency [3] - iBio reports a ROIC of -117.47% and a WACC of 6.80, leading to a negative ROIC to WACC ratio of -17.28, further illustrating struggles in capital efficiency [4] - Co-Diagnostics and Cocrystal Pharma also exhibit negative ROIC to WACC ratios of -13.01 and -13.80, respectively, highlighting ongoing challenges in generating adequate returns [4] - NanoViricides shows a ROIC of -111.71% and a WACC of 9.11, resulting in a negative ROIC to WACC ratio of -12.27, underscoring the difficulties faced by AIM's peers [5]

Capital Efficiency Analysis - ADC Therapeutics S.A. has a Return on Invested Capital (ROIC) of -54.62% and a Weighted Average Cost of Capital (WACC) of 20.44%, indicating significant challenges in capital efficiency [1][5] - Ciena Corporation shows a ROIC of 3.79% against a WACC of 8.87%, resulting in a ROIC to WACC ratio of 0.43, suggesting it is closer to covering its cost of capital [2][5] - COMSovereign Holding Corp. presents a ROIC of -694.61% and a WACC of 15.44%, leading to a ROIC to WACC ratio of -44.99, indicating severe inefficiencies [2][5] - Altair Engineering Inc. has a ROIC of 0.75% with a WACC of 10.57%, resulting in a ROIC to WACC ratio of 0.07, showing challenges similar to ADC Therapeutics [3][5] - ADTRAN Holdings, Inc. has a ROIC of -8.41% and a WACC of 9.27%, leading to a ROIC to WACC ratio of -0.91, indicating it is not generating sufficient returns [3][5] - Sanmina Corporation stands out with a ROIC of 9.69% and a WACC of 9.20%, resulting in a ROIC to WACC ratio of 1.05, making it the most efficient in capital utilization among the listed companies [4][5]

Sponsorship & Event - Amalgam is the official sponsor of Summit Singapore [1] - Summit Singapore will be held on September 29-30, 2025 [1] Product & Technology - Amalgam combines lending and trading into one DLEX [1] - DLEX unlocks capital efficiency and boosts LP yields by up to 60% [1]

Product Update - LBank launches margin trading feature [1] - Margin trading designed for greater capital efficiency [1] - Features include auto borrow & repay and shared collateral [1] Trading Features - Margin trading aims to unlock more possibilities for users [1]